IGM BIOSCIENCES
IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product... candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
IGM BIOSCIENCES
Industry:
Biotechnology Medical Therapeutics
Founded:
2010-01-01
Address:
Mountain View, California, United States
Country:
United States
Website Url:
http://www.igmbio.com
Total Employee:
101+
Status:
Active
Contact:
(650) 965-7873
Email Addresses:
[email protected]
Total Funding:
592 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Mobile Non Scaleable Content
Similar Organizations
Adagene
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
Nascent Biotech
Nascent Biotech is a biotechnology company building a portfolio of innovative therapeutic antibodies.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series C - IGM Biosciences
Haldor Topsoe Holding A/S
Haldor Topsoe Holding A/S investment in Series C - IGM Biosciences
Vivo Capital
Vivo Capital investment in Series C - IGM Biosciences
Janus Henderson Investors
Janus Henderson Investors investment in Series C - IGM Biosciences
Redmile Group
Redmile Group investment in Series C - IGM Biosciences
Haldor Topsoe Holding A/S
Haldor Topsoe Holding A/S investment in Series B - IGM Biosciences
Official Site Inspections
http://www.igmbio.com Semrush global rank: 1.03 M Semrush visits lastest month: 32.82 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IGM Biosciences"
About Us - IGM Biosciences
At IGM Biosciences, we believe that real innovation comes from looking beyond current approaches to envision a better way to address disease. Given the โฆSee details»
Team Members Archive - IGM Biosciences
Dr. Harler joined IGM in 2021. She is our Chief Executive Officer and a member of our Board of Directors. Prior to joining IGM she was Senior Vice President, Head of Immunology and โฆSee details»
IGM Biosciences - Crunchbase Company Profile & Funding
Organization. IGM Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โฆSee details»
IGM Biosciences Announces Strategic Pivot to Focus
Sep 30, 2024 โWe also want to sincerely thank Chris for his leadership of the clinical development organization as it expanded beyond oncology. We wish each of them the best in โฆSee details»
IGM Biosciences, Inc. | LinkedIn
For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 โฆSee details»
IGM Biosciences - Devex
Learn more about IGM Biosciences's jobs, projects, latest news, contact information and geographical presence. IGM Biosciences is pioneering a new class of antibody medicines for โฆSee details»
igmbio.com - Whois.com
Whois Lookup for igmbio.com. Login Sign up My Account Logout; Domains. ... Not Available From Registry Registrant Name: Registration Private Registrant Organization: Domains By Proxy, โฆSee details»
IGM Biosciences - Overview, News & Similar companies - ZoomInfo
Who is IGM Biosciences. About IGM Biosciences: Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating an d โฆSee details»
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on ...
IGM Biosciences, Inc. โ Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and โฆSee details»
Kim Michelson - IGM Biosciences
Prior to joining IGM, she served as Senior Vice President of Clinical Operations at Medpace, a global drug, biologic and medical device clinical research organization. Ms. Michelson has also โฆSee details»
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 โฆ
Mar 27, 2023 The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against โฆSee details»
Strategic Pivot to Autoimmunity - IGM Biosciences
Imvotamab deeply depletes tissue-resident B cells in Non-Human Primates (NHPs) Non-human primate data presentations โข 2023 American College of Rheumatology (ACR) Convergence โฆSee details»
News Release - investor.igmbio.com
Apr 10, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and โฆSee details»
IGM Biosciences Announces Strategic Pivot to Focus ... - BioSpace
Oct 1, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and โฆSee details»
Team Members Archive - Page 2 of 3 - IGM Biosciences
From February 2016 to August 2016, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research โฆSee details»
I G M B i os c i e n c e s , I n c
Ta bl e of C ont e nt s Inde x t o F i na nc i a l S t a t e m e nt s Tab l e of C on te n ts P age PA RT I It e m 1. B us i ne s s 3 It e m 1A .See details»
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on ...
Sep 30, 2024 --IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline โฆSee details»
Structure, Function, and Therapeutic Use of IgM Antibodies
Time were being given arbitrary names, in 1964 the World Health Organization de๏ฌned a nomenclature system for antibody isotypes. As a consequence -macroglobulin was renamed โฆSee details»
IGM Biosciences Announces FDA Clearance to Begin Clinical โฆ
May 31, 2023 For more information, please visit www.igmbio.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, โฆSee details»